Structure of Adverse Events Following Immunisation against Coronavirus Infection (COVID-19) in the Kyrgyz Republic

Structure of Adverse Events Following Immunisation against Coronavirus Infection (COVID-19) in the Kyrgyz Republic

There is considerable interest worldwide in developing safe and effective vaccines against COVID-19. Pharma-covigilance of adverse events following immunisation (AEFIs) is a key to making informed decisions regarding the global COVID-19 vaccination campaign. In the Kyrgyz Republic, there have been d...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. A. Zurdinova, Zh. O. Zhumagulova, A. T. Sharaeva, N. Sultanalieva
Format:	Article
Language:	Russian
Published:	Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» 2022-12-01
Series:	Безопасность и риск фармакотерапии
Subjects:	pharmacovigilance adverse event following immunisation aefi novel coronavirus infection covid-19 sars-cov-2 spontaneous reporting monitoring
Online Access:	https://www.risksafety.ru/jour/article/view/343
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Safety of COVID-19 vaccines
by: B. K. Romanov
Published: (2022-12-01)

Serious Adverse Events Following COVID 19 Vaccination in India: A Retrospective Study
by: Sruthikrishna Punathukandi, et al.
Published: (2025-01-01)

Adverse Effects Following Immunisation and Vaccine Hesitancy: A Qualitative Study in a South Indian District
by: Gopalan RB, et al.
Published: (2025-06-01)

Comparative safety evaluation of intranasal and intramuscular immunisation with Ad26 and Ad5-vectored vaccines to prevent coronavirus infection
by: E. V. Zuev, et al.
Published: (2023-10-01)

A scoping review of active, participant centred, digital adverse events following immunization (AEFI) surveillance of WHO approved COVID-19 vaccines: A Canadian immunization Research Network study
by: Mohamed Serhan, et al.
Published: (2024-12-01)

A national pharmacovigilance centre perspective on pandemic preparedness - lessons learned from the COVID-19 pandemic
by: Florence van Hunsel, et al.
Published: (2025-08-01)

Multisystem inflammatory syndrome in an adult after Covid-19 vaccination (MIS-V): a case report and review of published literature
by: Namirah Iftikhar, et al.
Published: (2024-09-01)

Short-term adverse events after COVAXIN vaccination in adolescents (15–18 Years) in Northern India: Frequency, predictors, and reporting behavior
by: Sujoy Bose, et al.
Published: (2025-07-01)

A STUDY TO ASSESS THE DISTRIBUTION OF SUSPECTED ADVERSE EVENTS FOLLOWING IMMUNISATION REPORTED IN A METROPOLITAN CITY IN INDIA
by: Sophie Simon, et al.
Published: (2025-01-01)

Adverse event reporting following immunization of hepatitis B vaccine: A 13-year review
by: Xiaoying Gong, et al.
Published: (2024-12-01)

ADVERSE EVENTS FOLLOWING PENTAVALENT VACCINE ADMINISTRATION: A DESCRIPTIVE STUDY IN THE INDIAN CONTEXT
by: Roop Sharma, et al.
Published: (2025-05-01)

Vaccine Safety International Monitoring
by: M. A. Darmostukova, et al.
Published: (2019-03-01)

Surveillance of psychogenic adverse events following immunization in Zhejiang, China, 2020–2023
by: Xuejiao Pan, et al.
Published: (2025-04-01)

Immunisation-related knowledge, attitudes and practices of mothers in Kinshasa, Democratic Republic of the Congo
by: Mala A. Mapatano, et al.
Published: (2008-04-01)

Factors influencing influenza vaccination coverage among kindergarten and primary school children in Zhejiang Province， 2023
by: LI Minchao, et al.
Published: (2025-01-01)

Surveillance of Adverse Events Following Varicella Vaccine Immunization in Zhejiang Province, China, from 2020 to 2022
by: Hui Liang, et al.
Published: (2025-01-01)

Reported Adverse Events Following SARS-CoV-2 Vaccinations in the Canadian Province of Alberta and Associated Risk Factors: A Retrospective Cohort Study
by: Yei Mansou, et al.
Published: (2024-12-01)

Timing Matters: Exploring the Role of the Time to Onset in Recall Bias for Adverse Events Following Immunization (AEFIs) of COVID-19 Vaccines from Spontaneous Reports
by: Joep Scholl, et al.
Published: (2025-04-01)

Approaches to Assessing the Safety of Medicines during the COVID-19 Pandemic Using the Example of Azithromycin
by: Yu. M. Gomon, et al.
Published: (2022-10-01)

Major Aspects of Detection and Monitoring of Adverse Reactions Associated with Cephalosporin Antibiotic Treatment
by: E. Yu. Demchenkova, et al.
Published: (2021-03-01)

Pharmacy Students’ Views on the Inclusion of Immunisation Training in the Pharmacy Curriculum
by: Nur Aisyah Amiza Mohd Nizam, et al.
Published: (2025-07-01)

Rational Organisation of Adverse Drug Reaction Monitoring
by: L. V. Shukil, et al.
Published: (2022-10-01)

IS THE PATIENT PARTNERSHIP INFORMATIVE IN PHARMACOVIGILANCE?
by: Yu. V. Muravyev
Published: (2017-09-01)

Analysis of Data on Adverse Drug Reactions and Functional Flaws of the Pharmacovigilance System Associated with Self-Treatment with Antibiotics
by: N. V. Verlan, et al.
Published: (2022-10-01)

DEBATABLE PROBLEMS OF PHARMACOVIGILANCE
by: Yu. V. Muravyev, et al.
Published: (2018-03-01)

Need and Rationale of the Adult Immunisation in India: A Review
by: Madhu Gupta, et al.
Published: (2025-03-01)

Real world pharmacovigilance comparison of viloxazine and dextroamphetamine adverse reaction profiles
by: Lijun Wang, et al.
Published: (2025-08-01)

Experience in Using Antiviral Agents for the Treatment of Novel Coronavirus Infection (COVID-19) in Kyrgyzstan
by: A. A. Zurdinova, et al.
Published: (2021-12-01)

The readiness of the spontaneous reporting system for COVID-19 vaccines safety monitoring in Croatia
by: Kovačić Barbara, et al.
Published: (2023-06-01)

Simulation-based assessment of digital twin systems for immunisation
by: Leonardo de Oliveira El-Warrak, et al.
Published: (2025-08-01)

Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Qi Song, et al.
Published: (2025-06-01)

Risk assessment of adverse drug reactions in elderly patients with cardiovascular diseases: Study on diagnostic accuracy
by: Ainura T. Sharaeva, et al.
Published: (2025-02-01)

Passive Immunisation in the Treatment of Infectious Diseases Related to Highly Potent Bacterial Toxins
by: Marta Prygiel, et al.
Published: (2024-12-01)

Advances in Pharmacovigilance in India: Role of Mobile Application
by: Rajpushpa Labh, et al.
Published: (2020-07-01)

Frequency of SARS-CoV-2 RNA Detection in Foreign Medical Students Vaccined against New Coronavirus Infection
by: O. A. Ryabtseva, et al.
Published: (2023-03-01)

Pharmacovigilance study of famciclovir in the Food and Drug administration adverse event reporting system database
by: Runan Fang, et al.
Published: (2024-11-01)

Evaluation of tolvaptan-associated hepatic disorder using different national pharmacovigilance databases
by: Takaya Uno, et al.
Published: (2024-10-01)

Updated insights into adverse events associated with mepolizumab: a disproportionality analysis from the FDA adverse event reporting system database
by: Shan Lin, et al.
Published: (2024-10-01)

Analysis of Adverse Reactions in Elderly Patients Based on Quantitative Methods of Signal Detection
by: K. E. Zalolochina, et al.
Published: (2021-10-01)

Delivering national immunisation programmes – a blanket opportunity for the pharmacy profession or a case of horses for courses?
by: Christina Wilson
Published: (2024-12-01)